| Drug Type Small molecule drug | 
| Synonyms 4,4'-bi-1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester, SY 801, SY-801 + [1] | 
| Action stimulants, inhibitors | 
| Mechanism HSP70 heat-shock proteins stimulants, PKC inhibitors(Protein kinase C inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date China (01 Jan 2001),  | 
| Regulation- | 
| Molecular FormulaC19H18O9 | 
| InChIKeyKXMTXZACPVCDMH-UHFFFAOYSA-N | 
| CAS Registry118159-48-1 | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Hepatitis, Viral, Human | China  | - | 21 Nov 2001 | 
| Fatty Liver | China  | - | 18 Oct 2001 | 
| Hepatitis B | China  | 01 Jan 2001 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Chemical and Drug Induced Liver Injury | Phase 3 | China  | 13 Dec 2021 | |
| Hepatitis, Chronic | Phase 1 | China  | 15 May 2015 | |
| Liver Cancer | Preclinical | China  | - | 
| Phase 2 | 241 | bdhtbxpfcm(aphoaposdv) = hclhjndgvb whagshgcun (mybrboyypv ) | Positive | 14 May 2022 | |||
| bdhtbxpfcm(aphoaposdv) = mkchubnqvc whagshgcun (mybrboyypv ) | 





